Risk factors

The company received FDA Breakthrough Device Designation for ExomeDx and GenomeDx, but it may not speed authorization or change approval standards.

Tariffs on imports from Canada, China and Mexico have increased product costs and could reduce gross margins.

Citi added interest-rate sensitivity and expanded Generative AI use as distinct risks.

Skyrizi and Rinvoq together generated approximately 42% of 2025 net revenues, concentrating revenue in two products.

New risk highlights dealer-management-system failure, integration, and technology-transition exposure; dealerships now use two DMS platforms.

Abbott plans about $20 billion in borrowings to fund the Exact Sciences acquisition, on top of $12.9 billion existing debt at year-end 2025.

A major Payor termination puts $322 million of revenue, including nearly all capitation revenue, at risk during 2026 transitions.

Array has shifted from operating a wireless carrier to a smaller tower, spectrum and investment business after the T-Mobile transaction closed August 1, 2025.

Acquiring Constructive adds direct mortgage origination and business-purpose loan risks, including third-party demand and integration challenges.

Akamai now identifies its AIC edge-inference platform as a direct competitor in the AI infrastructure market.

The company says prior material weaknesses have been remediated and now emphasizes required auditor attestation of internal controls.

Climate-related risks now flag possible disruption to NOAA or NCAR forecasting and modeling and NFIP authorization or administration.